Healthcare reality of the treatment of the high-risk multiple myeloma in Spain

被引：2
作者：
Hernandez-Rivas, Jose-Angel [1 ,2 ]
Gironella Mesa, Mercedes [3 ,4 ]
机构：
[1] Hosp Univ Infanta Leonor, Serv Hematol & Hemoterapia, Madrid, Spain
[2] Univ Complutense Madrid, Dept Med, Madrid, Spain
[3] Hosp Univ Vail dHebron, Serv Hematol, Barcelona, Spain
[4] Univ Autonoma Barcelona, Dept Med, Barcelona, Spain
来源：
MEDICINA CLINICA | 2020年 / 154卷 / 08期
关键词：
LENALIDOMIDE PLUS DEXAMETHASONE; TREATMENT STRATEGIES; CONSENSUS; STRATIFICATION; CARFILZOMIB; GUIDELINES; MANAGEMENT; SURVIVAL;
D O I：
10.1016/j.medcli.2019.10.006
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：315 / 319
页数：5
相关论文
共 50 条
  • [21] Cytogenetic and clinical marks for defining high-risk myeloma in the context of bortezomib treatment
    An, Gang
    Acharya, Chirag
    Deng, Shuhui
    Yi, Shuhua
    Xu, Yan
    Qin, Xiaoqi
    Sui, Weiwei
    Li, Zengjun
    Shi, Lihui
    Zang, Meirong
    Feng, Xiaoyan
    Hao, Mu
    Zou, Dehui
    Zhao, Yaozhong
    Qi, Junyuan
    Cheng, Tao
    Ru, Kun
    Wang, Jianxiang
    Tai, Yu-Tzu
    Qiu, Lugui
    EXPERIMENTAL HEMATOLOGY, 2015, 43 (03) : 168 - 176
  • [22] Quantification of clonal circulating plasma cells in newly diagnosed multiple myeloma: implications for redefining high-risk myeloma
    Gonsalves, W. I.
    Rajkumar, S. V.
    Gupta, V.
    Morice, W. G.
    Timm, M. M.
    Singh, P. P.
    Dispenzieri, A.
    Buadi, F. K.
    Lacy, M. Q.
    Kapoor, P.
    Gertz, M. A.
    Kumar, S. K.
    LEUKEMIA, 2014, 28 (10) : 2060 - 2065
  • [23] Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics
    Kumar, Shaji
    Fonseca, Rafael
    Ketterling, Rhett P.
    Dispenzieri, Angela
    Lacy, Martha Q.
    Gertz, Morie A.
    Hayman, Suzanne R.
    Buadi, Francis K.
    Dingli, David
    Knudson, Ryan A.
    Greenberg, Alexandra
    Russell, Stephen J.
    Zeldenrust, Steven R.
    Lust, John A.
    Kyle, Robert A.
    Bergsagel, Leif
    Rajkumar, S. Vincent
    BLOOD, 2012, 119 (09) : 2100 - 2105
  • [24] High-risk multiple myeloma: Redefining genetic, clinical, and functional high-risk disease in the era of molecular medicine and immunotherapy
    Rees, Matthew J.
    Kumar, Shaji
    AMERICAN JOURNAL OF HEMATOLOGY, 2024, 99 (08) : 1560 - 1575
  • [25] Adoptive Immunotherapy and High-Risk Myeloma
    Duane, Catherine
    O'Dwyer, Michael
    Glavey, Siobhan
    CANCERS, 2023, 15 (09)
  • [26] What Is Genomic High-Risk Myeloma?
    Davies, Faith E.
    Walker, Brian A.
    HEMATO, 2022, 3 (02): : 287 - 297
  • [27] Prognostic implications of abnormalities of chromosome 13 and the presence of multiple cytogenetic high-risk abnormalities in newly diagnosed multiple myeloma
    Binder, M.
    Rajkumar, S. V.
    Ketterling, R. P.
    Greipp, P. T.
    Dispenzieri, A.
    Lacy, M. Q.
    Gertz, M. A.
    Buadi, F. K.
    Hayman, S. R.
    Hwa, Y. L.
    Zeldenrust, S. R.
    Lust, J. A.
    Russell, S. J.
    Leung, N.
    Kapoor, P.
    Go, R. S.
    Gonsalves, W. I.
    Kyle, R. A.
    Kumar, S. K.
    BLOOD CANCER JOURNAL, 2017, 7 : e600 - e600
  • [28] Refining High-Risk Multiple Myeloma: Advancements in Genomic, Clinical, and Prognostic Criteria
    Martino, Enrica Antonia
    Mele, Giuseppe
    Vigna, Ernesto
    Morabito, Fortunato
    Gentile, Massimo
    MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES, 2024, 17 (01)
  • [29] Spinal metastases in multiple myeloma: A high-risk subgroup for ISS III patients
    Cossu, Giulia
    Terrier, Louis-Marie
    Benboubker, Lotfi
    Destrieux, Christophe
    Velut, Stephane
    Francois, Patrick
    Zemmoura, Ilyess
    Amelot, Aymeric
    SURGICAL ONCOLOGY-OXFORD, 2018, 27 (02): : 321 - 326
  • [30] Serum indicators in functional high-risk multiple myeloma patients undertaking proteasome inhibitors therapy: a retrospective study
    Zhan, Linquan
    Yuan, Dai
    Ge, Xueling
    Ding, Mei
    Wang, Jianhong
    Zhou, Xiangxiang
    Wang, Xin
    HEMATOLOGY, 2024, 29 (01)
12345